These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 28899971)

  • 1. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma.
    Heske CM; Davis MI; Baumgart JT; Wilson K; Gormally MV; Chen L; Zhang X; Ceribelli M; Duveau DY; Guha R; Ferrer M; Arnaldez FI; Ji J; Tran HL; Zhang Y; Mendoza A; Helman LJ; Thomas CJ
    Clin Cancer Res; 2017 Dec; 23(23):7301-7311. PubMed ID: 28899971
    [No Abstract]   [Full Text] [Related]  

  • 2. EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells.
    Mutz CN; Schwentner R; Aryee DNT; Bouchard EDJ; Mejia EM; Hatch GM; Kauer MO; Katschnig AM; Ban J; Garten A; Alonso J; Banerji V; Kovar H
    Oncotarget; 2017 Apr; 8(15):24679-24693. PubMed ID: 28160567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.
    Ordóñez JL; Amaral AT; Carcaboso AM; Herrero-Martín D; del Carmen García-Macías M; Sevillano V; Alonso D; Pascual-Pasto G; San-Segundo L; Vila-Ubach M; Rodrigues T; Fraile S; Teodosio C; Mayo-Iscar A; Aracil M; Galmarini CM; Tirado OM; Mora J; de Álava E
    Oncotarget; 2015 Aug; 6(22):18875-90. PubMed ID: 26056084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Ewing Family of Tumors Relies on BCL-2 and BCL-X
    Heisey DAR; Lochmann TL; Floros KV; Coon CM; Powell KM; Jacob S; Calbert ML; Ghotra MS; Stein GT; Maves YK; Smith SC; Benes CH; Leverson JD; Souers AJ; Boikos SA; Faber AC
    Clin Cancer Res; 2019 Mar; 25(5):1664-1675. PubMed ID: 30348635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.
    Smith MA; Reynolds CP; Kang MH; Kolb EA; Gorlick R; Carol H; Lock RB; Keir ST; Maris JM; Billups CA; Lyalin D; Kurmasheva RT; Houghton PJ
    Clin Cancer Res; 2015 Feb; 21(4):819-32. PubMed ID: 25500058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma.
    Guenther LM; Dharia NV; Ross L; Conway A; Robichaud AL; Catlett JL; Wechsler CS; Frank ES; Goodale A; Church AJ; Tseng YY; Guha R; McKnight CG; Janeway KA; Boehm JS; Mora J; Davis MI; Alexe G; Piccioni F; Stegmaier K
    Clin Cancer Res; 2019 Feb; 25(4):1343-1357. PubMed ID: 30397176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma.
    Wang S; Hwang EE; Guha R; O'Neill AF; Melong N; Veinotte CJ; Conway Saur A; Wuerthele K; Shen M; McKnight C; Alexe G; Lemieux ME; Wang A; Hughes E; Xu X; Boxer MB; Hall MD; Kung A; Berman JN; Davis MI; Stegmaier K; Crompton BD
    Clin Cancer Res; 2019 Jul; 25(14):4552-4566. PubMed ID: 30979745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors.
    Norris RE; Adamson PC; Nguyen VT; Fox E
    Pediatr Blood Cancer; 2014 Jan; 61(1):145-50. PubMed ID: 24038812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting NAD Metabolism: Rational Design, Synthesis and In Vitro Evaluation of NAMPT/PARP1 Dual-Target Inhibitors as Anti-Breast Cancer Agents.
    Li Y; Kong X; Chu X; Fu H; Feng X; Zhao C; Deng Y; Ge J
    Molecules; 2024 Jun; 29(12):. PubMed ID: 38930900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.
    Piacente F; Caffa I; Ravera S; Sociali G; Passalacqua M; Vellone VG; Becherini P; Reverberi D; Monacelli F; Ballestrero A; Odetti P; Cagnetta A; Cea M; Nahimana A; Duchosal M; Bruzzone S; Nencioni A
    Cancer Res; 2017 Jul; 77(14):3857-3869. PubMed ID: 28507103
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Lucena-Cacace A; Otero-Albiol D; Jiménez-García MP; Muñoz-Galvan S; Carnero A
    Clin Cancer Res; 2018 Mar; 24(5):1202-1215. PubMed ID: 29203587
    [No Abstract]   [Full Text] [Related]  

  • 12. Supplementation of nicotinic acid with NAMPT inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.
    O'Brien T; Oeh J; Xiao Y; Liang X; Vanderbilt A; Qin A; Yang L; Lee LB; Ly J; Cosino E; LaCap JA; Ogasawara A; Williams S; Nannini M; Liederer BM; Jackson P; Dragovich PS; Sampath D
    Neoplasia; 2013 Dec; 15(12):1314-29. PubMed ID: 24403854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting DNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6, Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition.
    Zhang P; Brinton LT; Williams K; Sher S; Orwick S; Tzung-Huei L; Mims AS; Coss CC; Kulp SK; Youssef Y; Chan WK; Mitchell S; Mustonen A; Cannon M; Phillips H; Lehman AM; Kauffman T; Beaver L; Canfield D; Grieselhuber NR; Alinari L; Sampath D; Yan P; Byrd JC; Blachly JS; Lapalombella R
    Clin Cancer Res; 2021 Apr; 27(8):2352-2366. PubMed ID: 33542077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells.
    Bajrami I; Kigozi A; Van Weverwijk A; Brough R; Frankum J; Lord CJ; Ashworth A
    EMBO Mol Med; 2012 Oct; 4(10):1087-96. PubMed ID: 22933245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
    Bai J; Liao C; Liu Y; Qin X; Chen J; Qiu Y; Qin D; Li Z; Tu ZC; Jiang S
    J Med Chem; 2016 Jun; 59(12):5766-79. PubMed ID: 27224875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combinatorial Drug Screening Identifies Ewing Sarcoma-specific Sensitivities.
    Radic-Sarikas B; Tsafou KP; Emdal KB; Papamarkou T; Huber KV; Mutz C; Toretsky JA; Bennett KL; Olsen JV; Brunak S; Kovar H; Superti-Furga G
    Mol Cancer Ther; 2017 Jan; 16(1):88-101. PubMed ID: 28062706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of nicotinamide phosphoribosyltransferase and depletion of nicotinamide adenine dinucleotide contribute to arsenic trioxide suppression of oral squamous cell carcinoma.
    Wang XY; Wang JZ; Gao L; Zhang FY; Wang Q; Liu KJ; Xiang B
    Toxicol Appl Pharmacol; 2017 Sep; 331():54-61. PubMed ID: 28501332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway.
    Engert F; Schneider C; Weiβ LM; Probst M; Fulda S
    Mol Cancer Ther; 2015 Dec; 14(12):2818-30. PubMed ID: 26438158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A fluorometric assay for high-throughput screening targeting nicotinamide phosphoribosyltransferase.
    Zhang RY; Qin Y; Lv XQ; Wang P; Xu TY; Zhang L; Miao CY
    Anal Biochem; 2011 May; 412(1):18-25. PubMed ID: 21211508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors.
    Chini CC; Guerrico AM; Nin V; Camacho-Pereira J; Escande C; Barbosa MT; Chini EN
    Clin Cancer Res; 2014 Jan; 20(1):120-30. PubMed ID: 24025713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.